Day One Biopharmaceuticals
Day One Biopharmaceuticals develops targeted therapies for pediatric cancer, including the FDA-approved OJEMDA™ (tovorafenib) for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma.
Company Overview
Day One Biopharmaceuticals focuses on developing targeted therapies for patients of all ages, with a special emphasis on pediatric cancer. It is committed to advancing medical and scientific knowledge in both pediatric and adult oncology through various initiatives, including clinical trials and investigator-sponsored research.
Products
Day One Biopharmaceuticals offers OJEMDA™ (tovorafenib), an FDA-approved treatment for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma. The company is also involved in the clinical development of investigational drugs like tovorafenib and pimasertib.
Clinical Trials and Research
Day One Biopharmaceuticals conducts clinical trials for multiple investigational drugs, including tovorafenib and pimasertib. The company supports investigator-sponsored research to advance treatment options in pediatric and adult oncology. It provides an expanded access policy for certain medicines outside the United States, contingent upon eligibility criteria.
Patient Support Program
The EveryDay Support From Day One™ program is offered by Day One Biopharmaceuticals to provide comprehensive support to patients. This program aims to assist patients throughout their treatment journey, providing them with necessary resources and guidance.
FDA Designations and Advocacy
Day One Biopharmaceuticals has received Breakthrough Therapy and Rare Pediatric Disease designations from the U.S. FDA for tovorafenib. The company actively participates in community and patient advocacy initiatives to ensure patient perspectives are integrated into drug development processes.